Immunic is trading 5.1% down at $13.01 as the stock faces profit-taking following yesterday’s biotech-driven rebound.
- The decline appears to reflect a shift toward weaker risk appetite in growth stocks, with no fresh company-specific news, trial updates, or analyst actions linked to the move.
- Broader biotech sentiment has turned more subdued compared to the sector-wide rally that helped lift the stock on July 27.